Fiche publication
Date publication
mai 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALI-YOUCEF Nassim
Tous les auteurs :
Dali-Youcef N, Mecili M, Ricci R, Andres E
Lien Pubmed
Résumé
Insulin resistance is a pathological condition that arises when insulin signaling is impaired, forcing beta-cells to produce more insulin in order to cope with body demands and to maintain glucose homeostasis. When the pancreas is no more able to support an appropriate insulin secretion, insulin resistance becomes decompensated and hyperglycemia is detected. One of the mechanisms leading to insulin resistance is low-grade inflammation that involves a number of protagonists such as inflammatory cytokines, lipids and their metabolites, reactive oxygen species (ROS), hypoxia and endoplasmic reticulum stress, and changes in gut microbiota profiles. We review here the molecular aspects of metabolic inflammation converging to insulin resistance and secondarily to type 2 diabetes. We also discuss the place of high-sensitivity C-reactive protein (hsCRP) in the assessment of metabolic inflammation and potential therapeutic interventions aimed to impede inflammation and therefore prevent insulin resistance.
Référence
Ann Med. 2013 May;45(3):242-53
